Showing 1-10 of about 142 articles.
Trillium Therapeutics Inc.
TORONTO, Dec. 03, 2018 (GLOBE NEWSWIRE) -- Trillium Therapeutics Inc. (NASDAQ/TSX: TRIL), a clinical stage immuno-oncology company developing innovative therapies for the treatment of cancer, today ...
Trillium Therapeutics Inc.
Positive clinical update on the intratumoral trial of TTI-621, a CD47 immune checkpoint inhibitor, presented at the 2018 EORTC CLTF meetingPositive clinical update on the intravenous trial of TTI-621 ...
Trillium Therapeutics Inc.
Data from intralesional trial in mycosis fungoides/Sézary syndrome patients continue to show promise, with rapid reductions in CAILS scores in the majority of patients and preliminary evidence of ...
Trillium Therapeutics Inc.
TORONTO, Sept. 27, 2018 (GLOBE NEWSWIRE) -- Trillium Therapeutics Inc. (NASDAQ/TSX: TRIL), a clinical stage immuno-oncology company developing innovative therapies for the treatment of cancer, ...
Trillium Therapeutics Inc.
Updated safety and efficacy data from the TTI-621 intravenous trial at the 16th Annual Discovery on Target ConferenceUpdated data from the TTI-621 intralesional trial in patients with mycosis ...
Trillium Therapeutics Inc.
TORONTO, Aug. 30, 2018 (GLOBE NEWSWIRE) -- Trillium Therapeutics Inc. (NASDAQ/TSX: TRIL), a clinical stage immuno-oncology company developing innovative therapies for the treatment of cancer, ...
Trillium Therapeutics Inc.
Increased focus on T cell lymphoma in lead program, TTI-621 Initiated dosing of TTI-622 (SIRPaFc IgG4) in phase 1a/1b clinical trial Recruited Dr. Yaping Shou as Chief Medical OfficerNegotiated ...
Trillium Therapeutics Inc.
TORONTO, June 19, 2018 (GLOBE NEWSWIRE) -- Trillium Therapeutics Inc. (NASDAQ:TRIL) (TSX:TRIL) (“Trillium” or the “Company”), a clinical stage immuno-oncology company developing innovative therapies ...
Trillium Therapeutics Inc.
TORONTO, June 15, 2018 (GLOBE NEWSWIRE) -- Trillium Therapeutics Inc. (NASDAQ:TRIL) (TSX:TRIL), a clinical stage immuno-oncology company developing innovative therapies for the treatment of cancer, ...
Trillium Therapeutics Inc.
TORONTO, June 14, 2018 (GLOBE NEWSWIRE) -- Trillium Therapeutics Inc. (NASDAQ:TRIL) (TSX:TRIL), a clinical stage immuno-oncology company developing innovative therapies for the treatment of cancer, ...
Showing 1-10 of about 142 articles.
